Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 5/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.77 |
| ▸ | LMNA | P02545 | 4/20 | 0.77 |
| ▸ | HTR1A | P08908 | 4/20 | 0.77 |
| ▸ | MAPT | P10636 | 4/20 | 0.77 |
| ▸ | DRD2 | P14416 | 4/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.77 |
| ▸ | TP53 | P04637 | 3/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.77 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.77 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.77 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.77 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.77 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.77 |
| ▸ | HTR2A | P28223 | 3/20 | 0.77 |
| ▸ | HTR2C | P28335 | 3/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlorproethazine SCHEMBL29818123 | 1.00 | CYP1A2 (0.77) | CYP1A2CYP2D6CYP2C19LMNAHTR1A | |
| Chlorproethazine SCHEMBL9724486 | 0.99 | LMNA (0.78) | CYP1A2CYP2D6CYP2C19LMNAHTR1A | |
| Chlorproethazine SCHEMBL1648952 | 0.98 | CYP1A2 (0.74) | CYP1A2CYP2D6CYP2C19LMNAHTR1A | |
| SCHEMBL142925 | 0.92 | ITGB2 (0.76) | CYP1A2CYP2D6CYP2C19LMNAHTR1A | |
| Hydrochloric Acid SCHEMBL7342890 | 0.91 | ITGB2 (0.74) | CYP1A2CYP2D6CYP2C19LMNAHTR1A | |
| SCHEMBL4247663 | 0.88 | CYP1A2 (0.71) | CYP1A2CYP2D6CYP2C19LMNAHTR1A | |
| Chlorpromazine SCHEMBL29367385 | 0.87 | CYP1A2 (1.00) | CYP1A2CYP2D6CYP2C19LMNAHTR1A | |
| Chlorpromazine SCHEMBL8321 | 0.87 | CYP1A2 (1.00) | CYP1A2CYP2D6CYP2C19LMNAHTR1A | |
| Chlorpromazine SCHEMBL29358018 | 0.87 | CYP1A2 (1.00) | CYP1A2CYP2D6CYP2C19LMNAHTR1A | |
| Chlorpromazine SCHEMBL23326209 | 0.86 | CYP1A2 (1.00) | CYP1A2CYP2D6CYP2C19LMNAHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 740 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4618973-A1 | METHODS OF SWITCHING NEUROPSYCHIATRIC MEDICATIONS USING ULOTARONT | Sumitomo Pharma America, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| US-20250179064-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | AUSPEX PHARMACEUTICALS LLC | 2025-06-05 | — | — | US | claimed |
| WO-2024107681-A1 | METHODS OF SWITCHING NEUROPSYCHIATRIC MEDICATIONS USING ULOTARONT | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| US-20240000810-A1 | USE OF CANNABINOIDS IN THE TREATMENT OF TOURETTE SYNDROME AND TIC DISORDERS | Orcosa Inc. (US) | 2024-01-04 | — | — | US | claimed |
| US-20230321073-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | Response IP Holding Company, LLC (US) | 2023-10-12 | — | — | US | claimed |
| EP-4192579-A2 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | Response IP Holding Company, LLC (US) | 2023-06-14 | — | — | EP | claimed |
| WO-2022032077-A2 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | REDUX THERAPEUTICS, LLC (US) | 2022-02-10 | — | — | WO | claimed |
| EP-3770159-A1 | BENZOQUINOLONE INHIBITOR OF VMAT2 | Auspex Pharmaceuticals, Inc. (US) | 2021-01-27 | — | — | EP | claimed |
| EP-3421469-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | Auspex Pharmaceuticals, Inc. (US) | 2019-01-02 | — | — | EP | claimed |
| EP-3351247-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | Auspex Pharmaceutical, Inc. (US) | 2018-07-25 | — | — | EP | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-0969845-B1 | NEW THERAPEUTIC COMBINATIONS OF MIRTAZAPINE AND ANTIPSYCHOTIC AGENTS, FOR THE TREATMENT OR PROPHYLAXIS OF PSYCHOTIC DISORDERS | AKZO NOBEL NV (NL) | 2006-03-01 | — | — | EP | claimed |
| CN-1226036-C | New therapeutic combinations of mirtazapine and antipsychotic agents, for treatment of prophylaxis of psychotic disorders | AKZO NOBEL NV (NL) | 2005-11-09 | — | — | CN | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| US-6150353-A | USE OF MIRTAZAPINE AND AN ANTIPSYCHOTIC DRUG COMBINATIONS ENHANCES THEEFFECT OF THE ANTIPSYCHOTIC AGENT TO BE USED AND ALLOW BETTER MANAGEMENT OF DRUG RELATED TOXICITY AND SIDE EFFECT | AKZO NOBEL N.V. (NL) | 2000-11-21 | — | — | US | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| CN-1251526-A | New therapeutic combinations of mirtazapine and antipsychotic agents, for treatment of prophylaxis of psychotic disorders | AKZO NOBEL NV (NL) | 2000-04-26 | — | — | CN | claimed |
| EP-0969845-A1 | NEW THERAPEUTIC COMBINATIONS OF MIRTAZAPINE AND ANTIPSYCHOTIC AGENTS, FOR THE TREATMENT OR PROPHYLAXIS OF PSYCHOTIC DISORDERS | Akzo Nobel N.V. (NL) | 2000-01-12 | — | — | EP | claimed |
| WO-1998043646-A1 | NEW THERAPEUTIC COMBINATIONS OF MIRTAZAPINE AND ANTIPSYCHOTIC AGENTS, FOR THE TREATMENT OR PROPHYLAXIS OF PSYCHOTIC DISORDERS | AKZO NOBEL N.V. (NL) | 1998-10-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179064-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | ACAT2, CPT1A, SLC18A2 | CYP1A2 327/4885CYP2D6 456/4885CYP2C19 427/4885 |
| US-20230321073-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | LIPC, CPT1A, CETP | CYP1A2 1032/4885CYP2D6 1018/4885CYP2C19 2181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.